clenbuterol has been researched along with Hypertrophy in 42 studies
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clenbuterol, a β₂-adrenergic agonist, increases the hypertrophy of skeletal muscle." | 7.78 | IGF and myostatin pathways are respectively induced during the earlier and the later stages of skeletal muscle hypertrophy induced by clenbuterol, a β₂-adrenergic agonist. ( Abo, T; Hamada, Y; Iida, RH; Kaneko, S; Suga, T; Yamada, H; Yamane, A, 2012) |
| "Analyses were performed to evaluate the roles of the beta1- and beta2-adrenergic receptors in the skeletal muscle hypertrophy and anti-atrophy response to the beta-adrenergic agonist, clenbuterol." | 7.71 | Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. ( Cody, DB; Hinkle, RT; Hodge, KMB; Isfort, RJ; Kobilka, BK; Sheldon, RJ, 2002) |
| " The beta 2-adrenoceptor agonist clenbuterol was used to investigate its potential to selectively induce skeletal muscle hypertrophy, particularly the latissimus dorsi muscle (LDM), independent of adverse effects on cardiac muscle." | 7.69 | Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. ( Boheler, KR; Petrou, M; Wynne, DG; Yacoub, MH, 1995) |
| " When rats were fed with clenbuterol for 7 days skeletal muscle mass increased by 21% in the tonic soleus and phasic plantaris muscles and a 16% hypertrophy of the heart was also induced." | 7.68 | Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterol-induced hypertrophy of cardiac and skeletal muscle of rats. ( Bain, P; Delday, MI; Maltin, CA; McMillan, DN; Noble, BS; Palmer, RM, 1990) |
| "05%) diet in rats had no effect in inducing muscle hypertrophy and in changing contractile properties, although it had some similar effects of clenbuterol on muscle gene expression." | 4.12 | Effects of long-term treatment with dietary theobromine on rat skeletal muscles. ( Inaoka, PT; Madokoro, S; Ohno-Shosaku, T; Sugimoto, N; Tanaka, S; Yamazaki, T, 2022) |
| "Clenbuterol (CB), a selective β2-adrenergic receptor (AR) agonist, induces muscle hypertrophy and counteracts muscle atrophy." | 3.83 | Role of phosphodiesterase 4 expression in the Epac1 signaling-dependent skeletal muscle hypertrophic action of clenbuterol. ( Cai, W; Fujita, T; Ishikawa, Y; Ito, A; Jin, H; Kawamura, N; Mototani, Y; Nariyama, M; Ohnuki, Y; Okumura, S; Saeki, Y; Shiozawa, K; Suita, K; Umeki, D; Yagisawa, Y, 2016) |
| "Clenbuterol is a β2 -adrenergic receptor agonist known to induce skeletal muscle hypertrophy and a slow-to-fast phenotypic shift." | 3.81 | Chronic clenbuterol treatment compromises force production without directly altering skeletal muscle contractile machinery. ( Bonnieu, A; Candau, RB; Cazorla, O; Chopard, A; Douillard, A; Galbès, O; Lacampagne, A; Lionne, C; Philippe, AG; Py, G; Ramonatxo, C; Sanchez, AM; Sirvent, P, 2015) |
| " We reported that clenbuterol (CB) induced masseter muscle hypertrophy and slow-to-fast myosin heavy chain (MHC) isoform transition through direct muscle β2-adrenergic receptor stimulation." | 3.81 | Protective Effects of Clenbuterol against Dexamethasone-Induced Masseter Muscle Atrophy and Myosin Heavy Chain Transition. ( Fujita, T; Mototani, Y; Nakamura, Y; Ohnuki, Y; Okumura, S; Saeki, Y; Shiozawa, K; Suita, K; Umeki, D, 2015) |
| "Chronic administration of clenbuterol (CB), a lipophilic β₂-adrenoceptor (β₂-AR) agonist, induces skeletal muscle hypertrophy and slow-to-fast fiber-type transitions in mammalian species, but the mechanism and pathophysiological roles of these changes have not been explored." | 3.79 | Role of masseter muscle β₂-adrenergic signaling in regulation of muscle activity, myosin heavy chain transition, and hypertrophy. ( Cai, W; Fujita, T; Jin, HL; Kawai, N; Mototani, Y; Ohnuki, Y; Okumura, S; Saeki, Y; Shiozawa, K; Tanaka, E; Umeki, D, 2013) |
| "In this study we investigated the combined effect of myostatin (MSTN) suppression and β-agonist (clenbuterol) administration on muscle hypertrophy and the phosphorylation of muscle 4E-BP1 and p70S6k, two downstream effectors of the Akt/mTOR anabolic pathway." | 3.77 | The muscle-hypertrophic effect of clenbuterol is additive to the hypertrophic effect of myostatin suppression. ( Kim, KH; Kim, YS; Yang, J, 2011) |
| "Our data reveal that clenbuterol-induced skeletal muscle hypertrophy is unable to mimic the beneficial clinical effects of increased musculature derived through targeted strength training in humans, in a rodent model of MNX-induced OA." | 3.76 | Beta2-adrenergic agonist-induced hypertrophy of the quadriceps skeletal muscle does not modulate disease severity in the rodent meniscectomy model of osteoarthritis. ( Bardsley, R; Doherty, M; Jones, SW; Maciewicz, RA; Parr, T; Tonge, DP, 2010) |
| "Clenbuterol, a beta-adrenoceptor agonist, has been reported to induce skeletal muscle hypertrophy." | 3.74 | Ultrastructural findings for the mitochondrial subpopulation of mice skeletal muscle after adrenergic stimulation by clenbuterol. ( Sharma, S; Sundal, S, 2007) |
| "Certain beta(2)-adrenoceptor agonists, such as clenbuterol, are known to elicit a muscle-specific anabolism or hypertrophy in both normal and catabolic muscle in a wide variety of species." | 3.74 | Clenbuterol increases muscle fiber size and GATA-2 protein in rat skeletal muscle in utero. ( Delday, MI; Downie, D; Maltin, CA; Sneddon, AA, 2008) |
| "Clenbuterol (Clen), a beta(2)-agonist, is known to produce skeletal and myocardial hypertrophy." | 3.73 | Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle. ( Karbowska, J; Kochan, Z; Latif, N; Malik, A; Smolenski, RT; Soppa, GK; Terracciano, CM; Yacoub, MH; Yuen, AH, 2005) |
| " The regulatory mechanism for the hypertrophy of skeletal muscles induced by clenbuterol is unclear." | 3.73 | Transforming growth factor betas are upregulated in the rat masseter muscle hypertrophied by clenbuterol, a beta2 adrenergic agonist. ( Akutsu, S; Shimada, A; Yamane, A, 2006) |
| "Global evaluation of gene expression after administration of clenbuterol identified changes in gene expression and overrepresented functional categories of genes that may regulate BA-induced muscle hypertrophy." | 3.73 | Changes in skeletal muscle gene expression following clenbuterol administration. ( McDaneld, TG; McIntyre, LM; Spurlock, DM, 2006) |
| " We studied changes in MLC2 phosphorylation in rats receiving three treatment conditions causing slow-to-fast transitions: 1) atrophy induced by 14 days of hindlimb suspension (HS), 2) hypertrophy induced by 14 days of clenbuterol administration (CB), and 3) 14 days of combined treatment (CB-HS)." | 3.72 | Increased phosphorylation of myosin light chain associated with slow-to-fast transition in rat soleus. ( Bozzo, C; Mounier, Y; Reggiani, C; Stevens, L; Toniolo, L, 2003) |
| "The relationship between myogenin or MyoD expression and hypertrophy of the rat soleus produced either by clenbuterol and 3,3', 5-triiodo-L-thyronine (CT) treatment or by surgical overload was examined." | 3.70 | Myogenin, MyoD, and myosin expression after pharmacologically and surgically induced hypertrophy. ( Greaser, ML; Mozdziak, PE; Schultz, E, 1998) |
| " The beta 2-adrenoceptor agonist clenbuterol was used to investigate its potential to selectively induce skeletal muscle hypertrophy, particularly the latissimus dorsi muscle (LDM), independent of adverse effects on cardiac muscle." | 3.69 | Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. ( Boheler, KR; Petrou, M; Wynne, DG; Yacoub, MH, 1995) |
| "The sympathomimetic agent, clenbuterol, induces a muscle-specific hypertrophy in both normal and catabolic muscle." | 3.68 | Satellite cells in innervated and denervated muscles treated with clenbuterol. ( Delday, MI; Maltin, CA, 1992) |
| " When rats were fed with clenbuterol for 7 days skeletal muscle mass increased by 21% in the tonic soleus and phasic plantaris muscles and a 16% hypertrophy of the heart was also induced." | 3.68 | Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterol-induced hypertrophy of cardiac and skeletal muscle of rats. ( Bain, P; Delday, MI; Maltin, CA; McMillan, DN; Noble, BS; Palmer, RM, 1990) |
| " Hypertrophy of soleus and plantaris muscles was induced either by severance of the tendon to the synergistic gastrocnemius (tenotomy) or by administration of the beta-adrenoceptor agonist clenbuterol." | 3.68 | Expression of c-myc and c-fos in rat skeletal muscle. Evidence for increased levels of c-myc mRNA during hypertrophy. ( Hesketh, JE; Whitelaw, PF, 1992) |
| " However, such doses may also induce myocyte death in the heart and skeletal muscles and hence may not be safe doses for humans." | 1.33 | Dose-dependent separation of the hypertrophic and myotoxic effects of the beta(2)-adrenergic receptor agonist clenbuterol in rat striated muscles. ( Burniston, JG; Clark, WA; Goldspink, DF; Tan, LB, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.76) | 18.7374 |
| 1990's | 10 (23.81) | 18.2507 |
| 2000's | 16 (38.10) | 29.6817 |
| 2010's | 12 (28.57) | 24.3611 |
| 2020's | 2 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, S | 1 |
| Sugimoto, N | 1 |
| Ohno-Shosaku, T | 1 |
| Madokoro, S | 1 |
| Inaoka, PT | 1 |
| Yamazaki, T | 1 |
| Kuramoto, N | 1 |
| Nomura, K | 1 |
| Kohno, D | 1 |
| Kitamura, T | 1 |
| Karsenty, G | 1 |
| Hosooka, T | 1 |
| Ogawa, W | 1 |
| Kim, J | 1 |
| Grotegut, CA | 1 |
| Wisler, JW | 1 |
| Li, T | 1 |
| Mao, L | 1 |
| Chen, M | 1 |
| Chen, W | 1 |
| Rosenberg, PB | 1 |
| Rockman, HA | 1 |
| Lefkowitz, RJ | 1 |
| Ohnuki, Y | 3 |
| Umeki, D | 3 |
| Cai, W | 2 |
| Kawai, N | 1 |
| Mototani, Y | 3 |
| Shiozawa, K | 3 |
| Jin, HL | 1 |
| Fujita, T | 3 |
| Tanaka, E | 1 |
| Saeki, Y | 3 |
| Okumura, S | 3 |
| Sumi, K | 1 |
| Higashi, S | 1 |
| Natsume, M | 1 |
| Kawahata, K | 1 |
| Nakazato, K | 1 |
| Py, G | 3 |
| Ramonatxo, C | 1 |
| Sirvent, P | 1 |
| Sanchez, AM | 1 |
| Philippe, AG | 1 |
| Douillard, A | 3 |
| Galbès, O | 3 |
| Lionne, C | 1 |
| Bonnieu, A | 3 |
| Chopard, A | 1 |
| Cazorla, O | 1 |
| Lacampagne, A | 1 |
| Candau, RB | 1 |
| Suita, K | 2 |
| Nakamura, Y | 1 |
| Nariyama, M | 1 |
| Ito, A | 1 |
| Kawamura, N | 1 |
| Yagisawa, Y | 1 |
| Jin, H | 1 |
| Ishikawa, Y | 1 |
| Woodall, BP | 1 |
| Woodall, MC | 1 |
| Luongo, TS | 1 |
| Grisanti, LA | 1 |
| Tilley, DG | 1 |
| Elrod, JW | 1 |
| Koch, WJ | 1 |
| Sato, S | 1 |
| Nomura, S | 1 |
| Kawano, F | 1 |
| Tanihata, J | 1 |
| Tachiyashiki, K | 1 |
| Imaizumi, K | 1 |
| Tonge, DP | 1 |
| Jones, SW | 1 |
| Parr, T | 1 |
| Bardsley, R | 1 |
| Doherty, M | 1 |
| Maciewicz, RA | 1 |
| Rossano, B | 2 |
| Vernus, B | 2 |
| Candau, R | 2 |
| Kim, KH | 1 |
| Kim, YS | 1 |
| Yang, J | 1 |
| Begue, G | 1 |
| Levin, J | 1 |
| Abo, T | 1 |
| Iida, RH | 1 |
| Kaneko, S | 1 |
| Suga, T | 1 |
| Yamada, H | 1 |
| Hamada, Y | 1 |
| Yamane, A | 3 |
| Bozzo, C | 1 |
| Stevens, L | 2 |
| Toniolo, L | 1 |
| Mounier, Y | 2 |
| Reggiani, C | 1 |
| Oishi, Y | 1 |
| Imoto, K | 1 |
| Ogata, T | 1 |
| Taniguchi, K | 1 |
| Matsumoto, H | 1 |
| Fukuoka, Y | 1 |
| Roy, RR | 1 |
| Soppa, GK | 1 |
| Smolenski, RT | 1 |
| Latif, N | 1 |
| Yuen, AH | 1 |
| Malik, A | 1 |
| Karbowska, J | 1 |
| Kochan, Z | 1 |
| Terracciano, CM | 1 |
| Yacoub, MH | 2 |
| Akutsu, S | 2 |
| Shimada, A | 2 |
| Burniston, JG | 1 |
| Clark, WA | 1 |
| Tan, LB | 1 |
| Goldspink, DF | 1 |
| Matsumoto, T | 1 |
| Wakana, N | 1 |
| Morito, M | 1 |
| Sundal, S | 2 |
| Katoch, SS | 1 |
| Sharma, S | 2 |
| Shi, H | 1 |
| Zeng, C | 1 |
| Ricome, A | 1 |
| Hannon, KM | 1 |
| Grant, AL | 1 |
| Gerrard, DE | 1 |
| Spurlock, DM | 1 |
| McDaneld, TG | 1 |
| McIntyre, LM | 1 |
| Downie, D | 1 |
| Delday, MI | 4 |
| Maltin, CA | 4 |
| Sneddon, AA | 1 |
| Rehfeldt, C | 1 |
| Weikard, R | 1 |
| Reichel, K | 1 |
| Petrou, M | 1 |
| Wynne, DG | 1 |
| Boheler, KR | 1 |
| Costelli, P | 1 |
| García-Martínez, C | 1 |
| Llovera, M | 1 |
| Carbó, N | 1 |
| López-Soriano, FJ | 1 |
| Agell, N | 1 |
| Tessitore, L | 1 |
| Baccino, FM | 1 |
| Argilés, JM | 1 |
| Mozdziak, PE | 1 |
| Greaser, ML | 1 |
| Schultz, E | 1 |
| Murphy, RJ | 1 |
| Béliveau, L | 2 |
| Gardiner, PF | 1 |
| Calderone, A | 2 |
| Rajab, P | 1 |
| Fox, J | 1 |
| Riaz, S | 1 |
| Tomlinson, D | 1 |
| Ball, D | 1 |
| Greenhaff, PL | 1 |
| Firinga, C | 1 |
| Gohlsch, B | 1 |
| Bastide, B | 1 |
| Pette, D | 1 |
| Lavoie, JL | 1 |
| Hinkle, RT | 1 |
| Hodge, KMB | 1 |
| Cody, DB | 1 |
| Sheldon, RJ | 1 |
| Kobilka, BK | 1 |
| Isfort, RJ | 1 |
| Agbenyega, ET | 1 |
| Wareham, AC | 1 |
| Palmer, RM | 1 |
| McMillan, DN | 1 |
| Noble, BS | 1 |
| Bain, P | 1 |
| Whitelaw, PF | 1 |
| Hesketh, JE | 1 |
| Horne, Z | 1 |
| Hesketh, J | 1 |
| Hay, SM | 1 |
| Smith, FG | 1 |
| Lobley, GE | 1 |
| Reeds, PJ | 1 |
| MacLennan, PA | 1 |
| Edwards, RH | 1 |
42 other studies available for clenbuterol and Hypertrophy
| Article | Year |
|---|---|
Effects of long-term treatment with dietary theobromine on rat skeletal muscles.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Diet; Hypertrophy; Male; Muscle, Skeletal; Rats; Rat | 2022 |
Role of PDK1 in skeletal muscle hypertrophy induced by mechanical load.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Adrenergic beta-Agonists; Animals; Cell Line; Clenbute | 2021 |
β-arrestin 1 regulates β2-adrenergic receptor-mediated skeletal muscle hypertrophy and contractility.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; beta-Arrestin 1; Calcium Signaling; Cells, Cultured; C | 2018 |
Role of masseter muscle β₂-adrenergic signaling in regulation of muscle activity, myosin heavy chain transition, and hypertrophy.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Central Nervous System; Clenbuterol; Electr | 2013 |
Temporal changes in ERK phosphorylation are harmonious with 4E-BP1, but not p70S6K, during clenbuterol-induced hypertrophy in the rat gastrocnemius.
Topics: Animals; Carrier Proteins; Clenbuterol; Extracellular Signal-Regulated MAP Kinases; Hypertrophy; Int | 2014 |
Chronic clenbuterol treatment compromises force production without directly altering skeletal muscle contractile machinery.
Topics: Action Potentials; Adenosine Triphosphatases; Adrenergic beta-Agonists; Animals; Calcium; Clenbutero | 2015 |
Protective Effects of Clenbuterol against Dexamethasone-Induced Masseter Muscle Atrophy and Myosin Heavy Chain Transition.
Topics: Administration, Oral; Animals; Body Weight; Clenbuterol; Dexamethasone; Energy Metabolism; Feeding B | 2015 |
Role of phosphodiesterase 4 expression in the Epac1 signaling-dependent skeletal muscle hypertrophic action of clenbuterol.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Cyclic Nucleotide Phosphodiesterases, Type 4; Gene E | 2016 |
Skeletal Muscle-specific G Protein-coupled Receptor Kinase 2 Ablation Alters Isolated Skeletal Muscle Mechanics and Enhances Clenbuterol-stimulated Hypertrophy.
Topics: Animals; Clenbuterol; G-Protein-Coupled Receptor Kinase 2; Hypertrophy; Mice; Mice, Knockout; Muscle | 2016 |
Effects of the beta2-agonist clenbuterol on beta1- and beta2-adrenoceptor mRNA expressions of rat skeletal and left ventricle muscles.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Gene Expression Regulation; Heart Ventricles; Hypert | 2008 |
Beta2-adrenergic agonist-induced hypertrophy of the quadriceps skeletal muscle does not modulate disease severity in the rodent meniscectomy model of osteoarthritis.
Topics: Adrenergic beta-Agonists; Animals; Body Weight; Clenbuterol; Disease Models, Animal; Hypertrophy; Ma | 2010 |
Time course in calpain activity and autolysis in slow and fast skeletal muscle during clenbuterol treatment.
Topics: Adrenergic beta-Agonists; Animals; Autolysis; Calpain; Cell Death; Clenbuterol; Hypertrophy; Male; M | 2011 |
The muscle-hypertrophic effect of clenbuterol is additive to the hypertrophic effect of myostatin suppression.
Topics: Anabolic Agents; Animals; Clenbuterol; Drug Synergism; Female; Hypertrophy; Mice; Mice, Inbred C57BL | 2011 |
Calpastatin overexpression in the skeletal muscle of mice prevents clenbuterol-induced muscle hypertrophy and phenotypic shift.
Topics: Animals; Calcium-Binding Proteins; Calpain; Cattle; Clenbuterol; Gene Expression Regulation; Hypertr | 2012 |
IGF and myostatin pathways are respectively induced during the earlier and the later stages of skeletal muscle hypertrophy induced by clenbuterol, a β₂-adrenergic agonist.
Topics: Administration, Oral; Adrenergic beta-Agonists; Animals; Blotting, Western; Clenbuterol; Hypertrophy | 2012 |
Increased phosphorylation of myosin light chain associated with slow-to-fast transition in rat soleus.
Topics: Adrenergic beta-Agonists; Animals; Atrophy; Cardiac Myosins; Clenbuterol; Hindlimb Suspension; Hyper | 2003 |
Calcineurin and heat-shock proteins modulation in clenbuterol-induced hypertrophied rat skeletal muscles.
Topics: Adrenergic beta-Agonists; Animals; Blotting, Western; Calcineurin; Clenbuterol; Drinking; Electropho | 2004 |
Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle.
Topics: Adrenergic beta-Agonists; Age Factors; Animals; Atrophy; Calcium; Carbohydrate Metabolism; Citric Ac | 2005 |
Transforming growth factor betas are upregulated in the rat masseter muscle hypertrophied by clenbuterol, a beta2 adrenergic agonist.
Topics: Adrenergic beta-Agonists; Animals; Body Weight; Clenbuterol; Fibroblast Growth Factors; Hepatocyte G | 2006 |
Dose-dependent separation of the hypertrophic and myotoxic effects of the beta(2)-adrenergic receptor agonist clenbuterol in rat striated muscles.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Clenbuterol; Dose-Response Relationship, Drug; Hypertr | 2006 |
The expressions of insulin-like growth factors, their receptors, and binding proteins are related to the mechanism regulating masseter muscle mass in the rat.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Hypertrophy; Insulin-Like Growth Factor Binding Prot | 2006 |
Metabolic and physiologic characteristics of skeletal muscle determine its response to clenbuterol treatment.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Hypertrophy; Male; Mice; Muscle Fibers, Fast-Twitch; | 2006 |
Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles.
Topics: Adrenergic beta-Agonists; Animals; Cell Cycle Proteins; Cell Line; Clenbuterol; Disease Models, Anim | 2007 |
Ultrastructural findings for the mitochondrial subpopulation of mice skeletal muscle after adrenergic stimulation by clenbuterol.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Diaphragm; Hypertrophy; Male; Mice; Microscopy, Elec | 2007 |
Changes in skeletal muscle gene expression following clenbuterol administration.
Topics: Adrenergic beta-Agonists; Animals; Blood Urea Nitrogen; Carrier Proteins; Clenbuterol; Cyclin-Depend | 2006 |
Clenbuterol increases muscle fiber size and GATA-2 protein in rat skeletal muscle in utero.
Topics: Adrenergic beta-Agonists; Animals; Cell Size; Clenbuterol; Female; Fetus; GATA2 Transcription Factor | 2008 |
[The effect of the beta-adrenergic agonist clenbuterol on the growth of skeletal muscles of rats].
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; DNA; Female; Hindlimb; Hypertrophy; Male; Muscle Dev | 1994 |
Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes.
Topics: Adipose Tissue; Animals; Base Sequence; Body Weight; Cardiomegaly; Clenbuterol; Forelimb; Hypertroph | 1995 |
Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Ascites; Clenbuterol; Corticosterone; Hypertr | 1995 |
Myogenin, MyoD, and myosin expression after pharmacologically and surgically induced hypertrophy.
Topics: Adrenergic beta-Antagonists; Animals; Blotting, Northern; Body Weight; Clenbuterol; Female; Hypertro | 1998 |
Nifedipine does not impede clenbuterol-stimulated muscle hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Blood Pressure; Body Weight; Calcium; Calcium Channels; Calcium C | 1999 |
Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adrenergic beta-Agonists; Animals; Clenbuterol; Energ | 2000 |
Effects of unweighting and clenbuterol on myosin light and heavy chains in fast and slow muscles of rat.
Topics: Adrenergic beta-Agonists; Animals; Atrophy; Body Weight; Clenbuterol; Hindlimb; Hindlimb Suspension; | 2000 |
A farnesyltransferase inhibitor attenuated beta-adrenergic receptor downregulation in rat skeletal muscle.
Topics: Adrenergic beta-Agonists; Alkyl and Aryl Transferases; Animals; Animals, Newborn; Body Weight; Cells | 2002 |
Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Female; Hypertrophy; Male; Mice; Mice, Knockout; Mus | 2002 |
Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone.
Topics: Animals; Clenbuterol; Dexamethasone; Hypertrophy; Male; Mice; Mice, Inbred C57BL; Muscle Proteins; M | 1992 |
Satellite cells in innervated and denervated muscles treated with clenbuterol.
Topics: Animals; Cell Division; Clenbuterol; Hypertrophy; Male; Microscopy, Electron; Muscle Denervation; Mu | 1992 |
Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterol-induced hypertrophy of cardiac and skeletal muscle of rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiomegaly; Clenbuterol; Cyclooxygenase Inhibito | 1990 |
Expression of c-myc and c-fos in rat skeletal muscle. Evidence for increased levels of c-myc mRNA during hypertrophy.
Topics: Aging; Animals; Blotting, Northern; Clenbuterol; Female; Gene Expression; Genes, fos; Genes, myc; Hy | 1992 |
Increased association of ribosomes with myofibrils during the skeletal-muscle hypertrophy induced either by the beta-adrenoceptor agonist clenbuterol or by tenotomy.
Topics: Animals; Antibodies; Clenbuterol; Hypertrophy; Male; Muscles; Myofibrils; Rats; Rats, Inbred Strains | 1990 |
The effect of the anabolic agent, clenbuterol, on overloaded rat skeletal muscle.
Topics: Animals; Calcium-Transporting ATPases; Clenbuterol; Ethanolamines; Hindlimb; Hypertrophy; Muscle Pro | 1987 |
Effects of clenbuterol and propranolol on muscle mass. Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy.
Topics: Animals; Body Composition; Clenbuterol; Cyclic AMP; Ethanolamines; Female; Glycogen; Heart; Hypertro | 1989 |